36.22

0.40% 0.135

Veracyte Inc (VCYT)

Overview News Price History Option Chain Financials Discussions Forecast

Veracyte Inc stock is traded at $36.22, with a volume of 268.76K. It is up +0.40% in the last 24 hours and up +0.63% over the past month. Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Previous Close:

$36.08

Open:

$35.97

24h Volume:

268.76K

Relative Volume:

0.27

Market Cap:

$2.85B

Revenue:

$399.58M

Net Income/Loss:

$-54.04M

P/E Ratio:

-48.29

EPS:

-0.75

Net Cash Flow:

$40.13M

1W Performance:

+0.71%

1M Performance:

+0.63%

6M Performance:

+19.36%

1Y Performance:

+5.58%

1-Day Range:

$35.30

$36.25

1-Week Range:

$34.84

$36.38

52-Week Range:

$22.61

$47.32

Veracyte Inc Stock (VCYT) Company Profile

Name

Veracyte Inc

Sector

Healthcare (1139)

Industry

Diagnostics & Research (53)

Phone

(650) 243-6300

Address

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

824

Twitter

@veracyte

Next Earnings Date

2025-02-24

Latest SEC Filings

VCYT's Discussions on Twitter

Compare VCYT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCYT Veracyte Inc	36.25	2.84B	399.58M	-54.04M	40.13M	-0.75
TMO Thermo Fisher Scientific Inc	562.32	213.17B	43.74B	6.59B	6.11B	17.30
DHR Danaher Corp	213.94	152.13B	24.27B	3.50B	5.02B	4.8589
IDXX Idexx Laboratories Inc	719.00	50.36B	4.04B	985.66M	774.34M	12.01
A Agilent Technologies Inc	144.44	41.49B	6.79B	1.22B	1.09B	4.2644
IQV Iqvia Holdings Inc	214.74	36.86B	15.90B	1.28B	2.21B	7.2842

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Canaccord Genuity	Hold
Mar-20-25	Initiated	Craig Hallum	Buy
Dec-05-24	Downgrade	Goldman	Buy → Neutral
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-16-24	Initiated	UBS	Buy
Oct-10-24	Initiated	Guggenheim	Buy
Feb-23-24	Reiterated	Needham	Buy
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Nov-18-21	Resumed	Goldman	Buy
Jun-15-21	Initiated	Raymond James	Outperform
Feb-18-21	Resumed	Needham	Buy
Jan-28-21	Initiated	Truist	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-09-20	Initiated	Morgan Stanley	Underweight
Jul-31-19	Initiated	Lake Street	Buy
Jul-02-19	Initiated	Needham	Buy
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Janney	Buy → Neutral
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-31-17	Resumed	BTIG Research	Buy
Nov-14-16	Resumed	Leerink Partners	Outperform
Dec-18-15	Initiated	Cantor Fitzgerald	Buy
Jun-11-15	Reiterated	Leerink Partners	Outperform
Nov-26-13	Initiated	William Blair	Outperform

View All

Veracyte Inc Stock (VCYT) Latest News

09:45 AM

Can Veracyte Inc. stock beat market expectations this quarter2025 Biggest Moves & Short-Term Trading Opportunity Alerts - newser.com

09:45 AM

08:31 AM

Heatmap analysis for Veracyte Inc. and competitors2025 Trading Volume Trends & Comprehensive Market Scan Insights - newser.com

08:31 AM

07:55 AM

Wakefield Asset Management LLLP Buys New Holdings in Veracyte, Inc. $VCYT - MarketBeat

07:55 AM

07:31 AM

What To Expect From Veracyte Inc (VCYT) Q3 2025 Earnings - Yahoo Finance

07:31 AM

05:14 AM

What to do if you’re stuck in Veracyte Inc.2025 Top Decliners & Community Verified Trade Alerts - newser.com

05:14 AM

03:20 AM